Keyword: Takeda

Shire nixed Takeda's $60 billion-plus buyout offer, Hanmi ditched lung cancer hopeful olmutinib, Grail is looking for $1 billion before Hong Kong IPO.

Just a few hours after Allergan confirmed that it was in buyout talks for hot target Shire, it said it didn’t intend to make an offer.

Shire has already rebuffed Takeda three times, and now the Japanese drugmaker faces a competing bidder—Allergan.

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.

Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.

The Shire bid Takeda’s been discussing is getting real. The Japanese drugmakers is gauging lender interest in financing the buy.

With Takeda weighing a Shire bid, other companies may be shopping the struggling biotech, too. Analysts are figuring out the who, what and how.

Drug materials are targets of U.S.-China trade war, analysts see more hope in the Takeda-Shire deal, China puts forward policies that favors generics over brands.

After initial doubts, some analysts now like Takeda's chances of pulling off a deal for embattled Shire.

Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.